Myelosuppression linezolid

Linezolid Myelosuppression monitor CBC once weekly if more than 2 weeks of therapy Peripheral and/or optic neuropathy has been reported with long-term therapy Mild MAO inhibitor evaluate for potential drug-drug or drug-food interactions... 

Myelosuppression Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid. Monitor complete blood counts weekly in patients who receive linezolid, particularly in those who receive linezolid for more than 2 weeks, those with preexisting myelosuppression, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibiotic therapy. 

The elimination of linezolid is by non-renal means (and does not involve CYP isoenzymes). It has weak MAOI activity. Myelosuppression, both dose- and time-dependent, occurs in 2-10% of patients with therapeutic doses. Linezolid interacts with serotonergic and adrenergic drugs. 

Linezolid has been associated with reversible myelosup-pression (14), which appears to be related to the duration of therapy, with a higher risk after more than 2 consecutive weeks of treatment (15). Myelosuppression with red cell hypoplasia has been reported in three patients taking linezolid 600 mg bd. The bone marrow changes were similar to those seen in reversible chloramphenicol toxicity. Another patient had sideroblastic anemia after taking linezolid for 2 months (16,17). 

---